Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the freeze-dried human rabies vaccine (ZFB-3 cells) developed by its wholly-owned subsidiary Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (“ZFB-3 cells”) has obtained the China Drug Clinical Trial Approval Notice (Notice Number: 2026LP03473) and agreed to carry out clinical trials to prevent rabies.

The freeze-dried human rabies vaccine (ZFB-3 cells) is a human diploid cell platform product independently developed by the company. The cell line is more suitable for large-scale cultivation and has independent intellectual property rights to overcome the problems of limited survival generation, limited continuous reproduction capacity, and lack of cellular resources for human diploid cell lines currently in use. The approval of the vaccine's clinical trial application is the result of the company focusing on innovative technology and strengthening core research. If the project progresses smoothly, it will further enrich the company's virus vaccine varieties, improve the company's product layout, and strengthen the company's competitive advantage and market position.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.